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1. INTRODUCTION 
1.1 Historical background 
The introduction of nonbiological materials into the human body has been recorded far back 
in human prehistory. The Mayan people have been known to use sea shells as dental implants 
as early as 600 A.D. and iron dental implants dated around 200 A.D. have been found in 
Europe (1). Surgical sutures made from silk have been recorded back to the period of the 
Egyptian civilization, whereas catgut sutures were used in the Middle Ages in Europe. 
Bioartificial organs, such as the artificial kidney and heart, were introduced in the middle of 
the 20th century, but most implants prior to 1950 had a low probability of success because of 
the lack of understanding of the biocompatibility and sterilization of the biomaterials 
employed. Since the 1960s most of the materials used in the fabrication of medical devices 
have been designed specifically for their intended application. Silicones, hydrogels and 
different types of bioglass were all developed in this time period together with the substantial 
growth of knowledge gained about biocompatibility and material-body interactions. This fact 
led to a significant increase in the use of biomaterials in the field of medicine (1), and the 
application area has grown especially fast over the past decades and covers now almost all the 
fields of clinical medicine (Fig. 1, Table 1). Biosensor applications for interventional 
procedures and monitoring are considered the most challenging area of this field in which 
multiple biomaterials are applied at the same site in combination with special requirements for 
the material properties.  
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Fig. 1. Clinical Applications of Biomaterials 
 
Biomaterials for long-term implantable devices should not just perform their intended 
function, but also be compatible with the host. The inflammatory response at the site of 
implantation is an important factor that may lead to sensor dysfunction. Inflammatory cells 
could affect the sensor signals by consuming substrate molecules that are also detected by the 
sensors (e.g. glucose), or attach to the device interface which may influence the membrane 
permeability. Biofouling of this sensor membrane is an important cause of sensor dysfunction 
(2). Proteins attached to the surface can impregnate the membrane and thus reduce the sensor 
performance by blocking access to the underlying transducer. In addition, cellular reaction to 
the implanted sensor will further enhance any sensor dysfunction and inactivation by 
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embalming the implant in a fibrous capsule that effectively separates the device from the rest 
of the body (2). Finally, the excretion of proteolytic enzymes and free radicals creates a local 
corrosive environment that may damage components of the sensor such as the polymeric 
membrane (2). In this context, the biocompatibility of biomaterials and the mechanisms 
involved in the inflammatory reaction to these biomaterials would be of paramount 
importance to understand considering the construction and intended function of the 
implantable device. 
Table 1. Some applications of synthetic materials and modified natural materials in medicine 
Application Type of material 
Intervention and monitoring 
Glucose sensors Pt, Ag/AgCl, Nafion, polycarbonate, cellulose 
Pacemakers Titanium, stainless steel, polyurethane 
Microdialysis Polyarylethersulphone, polyurethane 
Skeletal system 
Joint replacement (hip, 
knee) 
Titanium, Ti-Al-V alloy, stainless steel, 
polyethylene 
Bone plate for fracture 
fixation 
Stainless steel, cobalt-chromium alloy 
Bone cement Polymethyl methacrylate 
Bone defect repair Hydroxylapatite 
Artificial tendon and 
ligament 
Teflon, Dacron 
Dental implant for tooth 
fixation 
Titanium, Ti-Al-V alloy, stainless steel, 
polyethylene, alumina, calcium phosphate 
Cardiovascular system 
Blood vessel prosthesis Dacron, Teflon, polyurethane 
Heart valve Reprocessed tissue, stainless steel, carbon 
Catheter Silicone rubber, Teflon, polyurethane 
Organs 
Artificial heart Polyurethane 
Skin repair template Silicone-collagen composite 
Artificial kidney 
(hemodialyzer) 
Cellulose, polyacrylonitrile 
Heart-lung machine Silicone rubber 
Senses 
Cochlear replacement Platinum electrodes 
Intraocular lens Silicone-acrylate, hydrogel 
Corneal bandage Collagen, hydrogel 
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1.2 Definition of biocompatibility 
The International Standard ISO 10993 states that the basic biocompatibility requirements for a 
biomaterial is that it should be nontoxic, noncarcinogenic, nonantigenic, and nonmutagenic. 
Additionally, in applications that require direct contact with blood, the material must be of a 
nonthrombogenic nature that mitigates complications from thrombi and emboli (3;4). In 
clinical medicine some authors define biocompatibility of the dialysis membrane as the 
absence of any perturbation in the blood borne elements. This means in other words that there 
should be no adhesion or activation of blood cells or proteins absorption (5). Shaldon et al. 
defined biocompatibility as the quality of being mutually tolerant with life (6). 
Biocompatibility has traditionally been concerned with implantable devices that are intended 
to remain in place inside the body for long periods of time. In accordance to the definition of 
D. Williams, biocompatibility refers to the ability of a biomaterial to perform its desired 
function with respect to a medical therapy, without eliciting any undesirable local or systemic 
effects in the recipient or beneficiary of that therapy, but generating the most appropriate 
beneficial cellular or tissue response in that specific situation, and optimizing the clinically 
relevant performance of that therapy (7). This definition applies for biosensors that are 
intended to measure metabolic parameters by relying on the intact diffusion of tissue fluids 
across a porous membrane. 
1.3 Factors that influence the biocompatibility 
Biomaterials differ in their capacity to induce (or prevent) a biological response and there are 
several factors that needs to be considered in this respect. Literature has suggested that the 
chemical properties of the materials are the main contributor towards the biocompatible 
properties. It has been shown that the inherent surface hydrophilicity or hydrophobicity is one 
of the key parameters that affects the activation of the immune system, and the tendency have 
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been that hydrophobic materials exhibit a less desirable response (8-10). The current evidence 
support a theory that surface nucleophiles in combination with the presence of NH2 or 
hydroxyl groups on the material surface triggers a powerful activating potential. By contrast, 
negatively charged surfaces with the presence of COO- , SO3- and sialic acid appears to 
promote high-affinity association between the surface-bound C3b and the inhibitory factor H 
which prevents complement (and immune system) activation. Hence, the presence of 
chemical groups on the biomaterial surface determines its activation potential, which is 
currently evaluated by the degree of in vitro cytokines expression (11;12), in vivo cellular 
infiltration (13) and leukocytes activation with the corresponding expression of tissue factor 
(14). However, the surface topography of materials as well as the pore size of nanoporous 
membranes has also been found to contribute towards the biocompatibility. In this case the 
immune response is getting more potent as the pore size gets larger (15) whereas 
nanostructured surfaces shows a decrease in the immune system activation (16). The benefit 
of smaller pores (and nanostructured topography) is to limit the total accessible surface area 
that is available for protein absorption which in turn decreases the subsequent complement 
activation (9). Finally, the role of complement and the binding capacity of biomaterials 
towards factor H is another important feature that governs the biocompatibility. Surfaces that 
promote preferential binding of factor H and which does not favour binding of factor B will 
promote biocompatible properties (10;17-19). 
1.4 Immune response to biomaterials 
The immune system is responsible for the immediate recognition of foreign objects such as 
invading pathogens and artificial materials. The detection of pathogens is processed through a 
diverse set of pathogen-associated molecular patterns (PAMP). Because PAMPs are produced 
only by microorganisms, they are perceived by the innate immune system as a molecular 
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signature of infection, and their recognition leads to the induction of an immune response with 
a cascade activation and cell response (20;21). Non-microbial factors, such as damaged cells 
or cancer cells are recognized by alarmins, which together with PAMP are classified as 
danger-associated molecular patterns (DAMP). The activation of the innate immune system 
through these mechanisms provides an immediate immune response to pathogens or internal 
factors with subsequent activation of the inflammation cascade and the immune cells. One of 
these components, the inflammasome, have recently been related to biomaterials (22) since it 
appears to be a general mechanism for the initiation of inflammation in response to physical 
materials irrespective of their size and material properties. The activation of the 
inflammasome induces an inflammatory infiltrate that is dependent on the inflammasome 
components NOD-like leucine-rich repeat-containing 3 (Nlrp3), apoptosis-associated speck-
like protein containing CARD (Asc), and caspase-1. These components (except Nlrp3) also 
orchestrate the development of a fibrous reaction in the late phases of inflammation. Hence, 
the removal of the inflammasome in laboratory knock-out mice hinders the progression of a 
fibrous reaction possibly through the attenuation of profibrotic signals governed by the 
inflammasome (22). 
1.4.1 The complement system 
The complement system is an important part of the innate immunity and serves as a first-line 
of defence after the invasion of a foreign object (23). Complement consists of more than 30 
plasma and cell surface proteins (Fig. 2) and can be activated via the classical, the lectin and 
the alternative pathway (23;24). 
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Fig. 2. The Complement System 
 
The classical pathway is activated by an antigen-antibody complex or by acute phase proteins, 
whereas the lectin pathway is activated by conserved sugar epitopes like mannose present on 
the surface of the invading pathogens. The alternative pathway serves mainly as an amplifier 
of the initial classical or the lectin pathway activation, but can also be directly activated by 
synthetic surfaces (24). All the initial pathways converge at the C3 level by the formation of 
the enzyme C3 convertase that cleaves C3 to C3a and C3b molecules. C3b is a key molecule 
of the complement cascade that acts as an important opsonin and mediates further activation 
of the complement cascade by activating the enzyme C5 convertase that splits C5 into the 
intermediate products C5a and C5b. The C5b molecule initiates formation of the terminal 
complement complex (TCC). TCC exists in the fluid phase, but can also be inserted into the 
bacterial cell membrane, which makes it permeable, causing the bacteria to succumb from 
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osmotic stress. Additionally, C3a and C5a are both potent anaphylatoxins because of their 
tissue-sensitizing activity and with properties to activate white blood cells with initiation of 
inflammation (25). 
The activation of the complement system is tightly controlled by inhibitory molecules both in 
the soluble and membrane-associated form. Fluid phase complement regulators include factor 
H (an alternative pathways component that binds to C3b and competes for the binding site of 
factor B) and carboxipeptidase N (an anaphylatoxin inactivator) which inhibits all the three 
pathways. Soluble factors that regulate the classical and lectin pathways include the C1-
inhibitor (binds with C1qrs complex), factor I (C3b and C4b inactivator) and the C4b-binding 
protein. The membrane of host cells is also protected with membrane-bound complement 
regulators including complement receptor 1 (CR1), CD46 (MCP), CD55 (DAF), CD59 
(protectin) and complement receptor of the immunoglobulin superfamily (CRIg) (26-28) that 
prevent the complement system from attacking the cells of the body. The complement can be 
regarded as an early and fast recognition system that triggers inflammation processes at the 
site of implantation or pathogen invasion by mediating the immune cells activation. 
1.4.2 Coagulation and platelet 
The primary role of the haemostatic system is to arrest bleeding from injured blood vessels. 
However, the same process may produce adverse effects when an artificial material is 
introduced into human tissues and comes into contact with blood. The two main components 
of the haemostatic system, the coagulation cascade and platelets, do both equally participate 
in the inflammatory response to an implanted biomaterial, and the level of reaction may 
govern the function and lifespan of an implantable device. The process of coagulation 
proceeds through a cascade of reactions (Fig. 3) which converts inactive factors to 
enzymatically active ones. The coagulation cascade is traditionally divided up into the 
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intrinsic and extrinsic pathways. The intrinsic pathway initiates a cascade triggered by the 
surface contact with a biomaterial (surface-mediated reactions) whereas the extrinsic pathway 
is governed by TF and the proteolytic cleavage by other enzymes (1).  
 
Fig. 3 The Coagulation System 
Contact phase activation is thought to be the major trigger of the intrinsic pathway in the 
blood-biomaterial contact that occurs during the insertion of implantable devices, 
extracorporeal hemodialysis or artificial circulation as part of heart surgery (29). The 
components of the contact activation system such as prekallikrein, high molecular weight 
kininogen, coagulation factor XI and coagulation factor XII (Hageman factor) do all attach to 
foreign surfaces. Following attachment, the autoactivation of FXII to FXIIa cleaves 
20 
 
prekallikrein to kallikrein and initiates the FXII activation loop which activates the intrinsic 
pathway through the generation of the FXIIa. 
The physiological initiator of the extrinsic pathway is TF, and the expression of TF on 
damaged cells at the site of vascular injury or by monocytes results in blood coagulation with 
fibrin formation at the site of injury or implantation (30-32). Factor VII (FVII) binds to TF on 
the cell membranes and is activated to FVIIa to form the TF-VIIa complex (33) which cleaves 
and activates Factor X. The two pathways converge into a common pathway at the FX level 
resulting in the formation of a fibrin clot with the aid of thrombin on fibrinogen (30). The two 
coagulation pathways are not independent and closely interact. The extrinsic enzymatic 
complex TF-FVII is responsible for the onset of the coagulation cascade while the contact 
phase is a major player in the propagation phase (30;34). 
Platelets are nonnucleated cells that are produced in the bone marrow and circulate in the 
blood occupying approximately 0,3 % of the blood volume. The function of the platelets is to 
arrest bleeding by forming an initial platelet plug which is stabilized by catalyzing the 
coagulation reaction with the formation of fibrin (1). Platelet contain substantial quantity of 
muscle proteins that initiate platelet contraction, and three types of cytoplasmic storage 
granules (35;36): 
 α-granules, which contains fibrinogen, coagulation factors V and VIII as well as the 
platelet-specific proteins platelet factor 4 (PF-4), β-thromboglobulin (BTG) and 
chondroitin sulfate A 
 Dense granules containing adenosine diphosphate (ADP), calcium and serotonin 
 Lysosomal granules containing hydrolytic enzymes 
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Consequently, the adhesion and activation of platelets on a biomaterial surface leads to the 
subsequent release of PF-4 and BTG from the intracellular α-granules. P-selectin, a cell-
surface glycoprotein belonging to the selectin family, and which is released from the α-
granules, mediates the adhesion of activated platelets to neutrophils and monocytes. All of 
these factors will in turn influence the activation of other platelets, as well as modulating the 
coagulation process and inflammation (32;37;38). 
1.4.3 Polymorphonuclear leukocytes and monocytes 
Neutrophils or polymorphonuclear leukocytes (PMN) represents 40-60% of the white blood 
cells and is an important part of the inflammatory response. PMN appears at the site of 
implantation within the first seconds (39;40) and the expression of adhesion molecules on a 
surface modulates the inflammatory response. An important group of adhesion molecules 
include the CD11/CD18 family. Inflammatory mediators like cytokines, chemokines and 
anaphylatoxins stimulate the rapid increase in these adhesion molecules on the leukocyte 
surface as well as increased PMN adhesion to biomaterial surface (39;41). The adhesion of 
PMN to material surfaces and the PMN’s activation by the inflammatory molecules from the 
complement, coagulation and platelet systems triggers the release of a new set of bioactive 
molecules from the PMN which induce the production of reactive oxygen intermediates 
(ROI). ROI’s are essential mediators of signalling by many cytokine and hormone receptors, 
such as those for insulin, platelet-derived growth factor, fibroblast growth factor, nerve 
growth factor, TNF and angiotensin. The azurophilic granules of PMN contains 
myeloperoxidase (MPO), a glycosylated protein which exerts microbicidal effects and which 
are able to convert the relatively innocuous H2O2 into the much more powerful hypochlorous 
acid, hypobromous acid and hypoiodous acid, which are all powerful bactericidal compounds 
(42;43). The PMN and monocytes does also produce a broad spectrum of cytokines and 
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chemokines that mediates further cells activation that amplifies the immune response at the 
site of implantation (42-44). Pro-inflammatory cytokines like tumor necrosis factor-α (TNF-
α), interleukin-6 (IL-6) and interleukin-1β (IL-1β) induce an acute phase response. The 
chemokines family also contribute to inflammation process by triggering the local 
accumulation of inflammatory cells at the site of implantation (45). Interleukin-8 (IL-8), 
macrophage inflammatory protein-1β (MIP-1β) and monocyte chemoattractant protein-1 
(MCP-1) chemotactically attracts PMN, monocytes/macrophages and play an crucial role in 
the development of chronic inflammation through the recruitment of immune cells to the site 
of injury (12). 
The close interaction between the complement system, haemostatic system and the cellular 
components of the innate immune system plays a collective role in determining the 
biocompatibility of a material. The contact activation system as well as thrombin and plasmin 
are able to cleave complement component in vitro (46;47). Complement activation leads to 
coagulation activation and the C5a-mediated upregulation of TF, which is the potent initiator 
of the extrinsic pathway of coagulation (48-50). Platelet activation during thrombotic events 
initiates the activation of complement (51) and the contact system (52), which in turn leads to 
inflammation. Thrombin receptor activated platelet are strong promoters of inflammation, 
since chondroitin sulfate A, released from the α-granules during platelet activation, activates 
complement in the fluid phase and generates anaphylatoxins that induce leukocyte activation 
(26;48;53;54). Thus it is important to evaluate different cascades and cells in a single test 
model to understand the overall mechanisms governing the biocompatibility of biosensors 
(30;55;56). 
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1.5 Immune system activation following materials implantation 
1.5.1 Acute inflammation 
The molecular mechanisms of acute inflammation are poorly understood. Yet, literature have 
identified the most important components such as the role that inflammasome activation, as 
well as plasma membrane cholesterol, and Syk signalling contributing to acute immune 
response to biomaterial implantation (22). 
The immune response to artificial materials starts by coating the surface with a protein film 
composed from albumin, immunoglobulin G (IgG) and fibrinogen (17;57;58), that initiates 
complement activation. The study performed by Gifford (59) using MALDI-TOF mass 
spectrometry, showed that the mechanism of protein absorption was time-dependent with 
albumin being the first protein to be absorbed, followed by IgG and then fibrinogen. The 
absorbed proteins have been shown to activate the complement system through the classical 
pathway (60) in which the absorbed C3 protein, generated in this process, is able to serve as a 
nucleation point for the subsequent activation of the alternative pathway. Once C3b is 
generated and covalently bonded to the protein coat, the amplification loop of the alternative 
pathway can be triggered (18;61;62). Further, C3b that is attached to the material surface can 
physically shield the underlying proteins, including C1q and IgG, and thereby halting 
activation via the classical pathway (61). 
The C3b and the anaphylatoxins C3a and C5a that is generated as a result of complement 
activation acts as ligands for the receptors on PMN and monocytes that can trigger 
inflammation and the release of pro-inflammatory cytokines and chemokines (62). The 
activation products of complement do also trigger inflammatory cell activation with 
expression of the adhesion molecules CD11/CD18 on the PMN surface and the expression of 
TF on monocytes. The activated PMN that adhere to complement- and immunoglobulin 
24 
 
coated biomaterial surfaces may release MPO and lactoferrin from their granules. The amount 
of enzymes that is released corresponds to the size of the material surface in which larger 
biomaterial implants have been found to release a great amount of enzyme from activated 
cells (39). 
The acute inflammatory response to biomaterials is usually resolved within several days, 
depending on the extent of the injury at the implant site and the type of biomaterial used. The 
extent of tissue damage during implantation will lead to a longer acute inflammation period 
concomitant with an increasing amount of fibrous tissue formed at the site of injury (63). 
1.5.2 Chronic inflammation 
Chronic inflammation follows the acute phase and is identified by the presence of 
macrophages and lymphocytes at the site of implantation together with the proliferation of 
blood vessels and the formation of connective tissue (64;65). The macrophages are the most 
important cells governing chronic inflammation because they secrete biologically active 
products like chemotactic factors, reactive oxygen metabolites, complement proteins, 
coagulation factors and cytokines. The chronic inflammation is normally resolved within a 
limit period of time if this process is triggered by biocompatible materials (39). Classically, 
the development of granulation tissue has been considered as a part of the chronic 
inflammation process, but because of the unique tissue-biomaterials interaction it has become 
preferable to consider the formation of foreign body giant cells (FBGC) as a separate process 
that follows chronic inflammation together with the development of granulation tissue. On a 
molecular level chronic inflammation and formation of FBGC is mediated with the 
inflammasome as well as being dependent on Asc and caspase-1 (22). 
The foreign body reaction to biomaterials is identified by the presence of FBGC and 
granulation tissue, which consist of macrophages and fibroblasts. Macrophage activation and 
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fusion have been identified as the critical cellular events leading to the formation of FBGC, 
including the induction of E-cadherin, Rac1 activation, and secretion of matrix 
metalloproteinase-9 (66). Both macrophages and FBGC can release mediators of degradation 
such as ROIs, oxygen free radicals and proteolytic enzymes. Both adherent macrophages and 
FBGC in the foreign body reaction are known to assist in the degradation of biomaterials, and 
as stressed earlier, both the shape, material and surface topography of the biomaterial 
determines the degree and severity of the foreign body reaction. A large amount of FBGC has 
been found for porous materials compared to smooth-surface implants, and which will result 
in fibrosis as a significant component at the implant site (39;63). Recently, though, it has been 
suggested that a textured rather than a smooth surface could lead to an improved long term 
sensor performance by increasing the vascularisation around the implant (67;68). Although 
compelling evidence links implant topology with the nature of the tissue response, a link 
between the surface texturing and sensor performance, particularly biofouling, remains poorly 
understood (69).  
1.5.3 Fibrous encapsulation 
The end-stage of the healing process related to a biomaterial implant is generally 
characterised by some degree of fibrosis that in part is dependent upon the extent of the injury 
or tissue defect that is created during the implantation procedure. Regeneration with 
replacement of granulation tissue by connective tissue leads to the formation of a fibrous 
capsule that encloses the layer of FBGC on the implant surface. The extent of this fibrous 
encapsulation as well as the degree and duration of chronic inflammation, foreign body 
reaction and the subsequent healing process, is determined by the acute inflammation and the 
presence of cytokines, chemoattractants, growth factors and macrophages. 
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In order to investigate these complex interactions between the different arms of the 
inflammatory network in vitro, it is necessary to apply a suitable model. There are several in 
vitro models that can be explored in biomaterial research. Serum and isolated cells are used to 
examine separate biological processes, whereas tissue cultures are a popular method to 
investigate macrophage reaction and the cytotoxicity effects of biomaterials. More complex 
model based on whole blood will facilitate the investigation of the interaction between 
cascades of innate immunity and the sequences of processes following material implantation. 
1.6 Models used to investigate the biocompatibility of materials 
1.6.1 Serum and isolated cells 
Investigations of the initial complement activation and protein adsorption on a material 
surface requires the use of a simple in vitro serum model. Serum contains all the blood plasma 
proteins except fibrinogen, and since there are no cells present (i.e. no biological turnover), 
any activation product from complement, including C5a can be detected (70). Serum can also 
be used to examine the activation of different complement pathways. For instance, the role of 
the alternative pathway can be investigated by blocking the classical pathway with EGTA and 
Mg2+. In contrast, a low concentration of the C3-inhibitor compstatin blocks the formation of 
the convertase and permits only the classical pathway to operate (61). 
A separate evaluation of blood cells requires the use of an isolated cell model. Platelet-rich 
plasma (PRP) is the preferred option to evaluate either platelet adhesion to a materials surface, 
platelet activation, the release of granules as well as the interaction between platelet and 
plasma proteins (71-74). PMN’s that are isolated from whole blood and resuspended in a 
buffered solution can be used as a model to investigate PNM activation by biomaterials (40), 
whereas monocytes and lymphocytes can be used to examine cytokines and chemokines 
production respectively (12). However the activation of the coagulation cascade is also 
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dependent on the cross-talk between the contact activation system (32), blood cells and the 
complement system (30). Several studies have shown that thrombin plays an important part in 
the activation of platelets (75;76) and the use of the PRP model makes it impossible to 
explore the interaction between blood cells and platelet compared to the whole-blood model. 
1.6.2 Cell and tissue cultures 
The tissue culture method was introduced in 1965 as means to evaluate the toxicity of 
polymeric materials (77;78). It was later standardized by the American Society for Testing 
and Materials (ASTM) and is currently used to perform cytotoxicity screens in vitro by 
offering higher reported sensitivities to toxins than that of most animal models (79). Cell lines 
that have been developed for growth in vitro are preferred to primary cells (that are freshly 
harvested from live organisms), since they offer a comparable cell type that improves the 
reproducibility of the assays and thereby reduce the variability among the different 
laboratories (1). For instance, mouse fibroblast cells (L-929) exposed to biomaterials for 
several days is commonly used to test for leachable toxic substances in the material and for 
any residual solvents used during the material preparation (80). In accordance to the 
recommendation of the International Standard Organization ISO 10993-5 “Established cell 
lines are preferred and where used shall be obtained from recognized repositories” (81). 
Qualitative assessment of cytochemical staining can be used to assess changes in general 
morphology, vacuolization, cell lysis and membrane integrity (82). Quantitative tests measure 
the parameters of cell death, inhibition of cell growth, cell proliferation and colony formation 
(81;83). 
Appropriate mammalian cell cultures can also be used to investigate the carcinogenicity and 
genotoxicity of a material. These cell cultures are assessed by the degree of gene mutations, 
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changes in chromosome structure (and number) as well as other DNA or gene related 
toxicities caused by the materials and/or their extracts (83;84). 
1.6.3 Whole blood 
To investigate the role of complement in the complex inflammatory network and to evaluate 
the role of blood cells, all the potential cellular and fluid-phase mediators needs to be present 
simultaneously (85). Such cross-talk can be achieved in vitro using a whole-blood model. 
Blood will readily coagulate as a result of protein adsorption to a material interface and the 
absence of regulators on the container walls requires the use of a soluble artificial 
anticoagulant. Both ethylenediaminetetraacetic acid (EDTA) and citrate are known to inhibit 
complement activation and should be avoided to investigate complement activation (70). 
Heparin is widely used in biocompatibility experiments although it inhibits complement 
activation in high concentration and enhance the activation at low concentrations (85). 
Heparin do also possess various direct effects on platelet and leukocytes (86;87), which 
excludes it as an optimal anticoagulant in models to study the inflammatory network. In the 
past decade, a highly specific recombinant thrombin inhibitor, lepirudin, has come into play 
with respect to in vitro blood research (85;88). Lepirudin binds to active thrombin, and 
irreversible inactivates it without any adverse effects to the rest of coagulation cascade and 
complement system (89). The addition of EDTA following the end of an experimental process 
prevents further activation of the blood sample during storage. This makes whole-blood 
anticoagulated with lepirudin the most native and suitable model used to investigate 
complement activation and the inflammatory processes induced by artificial materials.  
In contrast, the best alternative that exists in order to evaluate the activation of the coagulation 
system and platelets, is to use native whole blood without any additives. As shown in several 
studies (75;76), thrombin have an important role in the propagation of coagulation and 
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platelets activation. The using of lepirudin as an anticoagulant blocks the thrombin generation 
that can have an important effect on a native haemostatic system in vitro. To prevent blood 
coagulation after contact with the container walls, different coating methods can be used. 
Heparin that is immobilized to an artificial surface has been shown to be the best acceptable 
candidate for this purpose used both in clinical practice (90;91) as well as research (92-96). 
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2. AIMS OF THE STUDIES 
The aim of this project was to evaluate the in vitro biocompatibility of a selected group of 
candidate materials intended for use in a microfabricated implantable glucose sensor. The 
evaluated materials are also relevant for other implantable devices and therefore can be 
applied in different application areas. The material samples were incubated in standard 24 
well polystyrene plates at 370C using either a serum, or a whole-blood model with a soluble 
anticoagulant. These models permitted the examination of both the complement system as 
well as the different cascades involving immune cells that closely mimic the in vivo 
environment. A novel whole blood model based on the incubation in heparin coated 
polystyrene wells permitted the investigation of complement related to the coagulation and 
platelet activation process without the use of a soluble anticoagulant. 
The assays were selected in accordance to the International standard ISO 10993 and covered 
all the parts of the innate immunity cascades, the cells activation and the coagulation cascade. 
The activation of complement, PMN’s, the inflammatory response, the coagulation and the 
platelet system were evaluated in separate in vitro studies. The role of the complement system 
was examined by using specific complement inhibitors. 
Study 1 
The aim of this study was to evaluate complement activation by different candidate materials 
of an implantable microfabricated glucose sensor with the aid of a serum model. 
Study 2 
The aim of this study was to perform an in vitro analysis of PMN activation following 
exposure to selected candidate materials for an osmotic glucose sensor and to evaluate how 
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the activation of complement contributes to the activation of PMN in response to such 
materials.  
Study 3 
The aim of this study was to examine the activation of the in vitro inflammatory network in 
response to direct contact with candidate materials that were intended for use in 
microfabricated implantable glucose sensor, and the role of the complement system as a 
trigger of this process. 
Study 4 
The aim of this study was to evaluate the in vitro coagulation potential of selected membrane 
materials that is of interest for use in implantable microfabricated glucose sensor based on a 
modified whole blood model without soluble anticoagulant in heparin-coated wells. The role 
of complement in the activation of coagulation and platelet by biomaterials was explored. 
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3. MATERIALS AND METHODS 
3.1 Sensor architecture 
The biomaterials that were selected for investigation in this study were all candidate materials 
that would form part of a microfabricated osmotic glucose sensor under development by 
Lifecare AS. These materials were divided up into four different groups depending on which 
parts of the sensor they would be implemented (capsule, membrane, carrier and sealing). The 
sensor microimplant is built around a carrier of low temperature co-fired ceramics (LTCC) 
which is a multilayer ceramic platform that permit integration of microelectronic circuit 
components in 3 dimensions. This enables an ultracompact and thermally stable platform 
architecture that is currently used in the artificial pacemaker. Consequently, a choice of two 
LTCC materials that differ slightly in their processing parameters are included in this study, 
CeramTec GC (CT) and DuPont 951 (DP). The membrane and pressure transducer are 
attached to the LTCC using a two component epoxy resin Epo-Tek 353ND (ETek) that cures 
with temperature. This adhesive also acts as a sealing material that protects the electrical 
connections from moisture. However, the small distances (<250μm) between the electrical 
connections and the aqueous environment in the sensor cavity prompted two additional 
sealant materials to be considered; silicone 3140 (S3140) and 3145 (S3145) due to their good 
water repellent properties. A seal made of these materials will also act as a buffer between the 
sensor components and the external capsule. The membrane and control chip are all made 
from silicon (Si) and its glass derivative silicon dioxide (SiO2). Additional membrane 
materials include anodic aluminium oxide (AAO) and the polymers cellulose ester (CM), 
polyamide (PAR, PATF) and polycarbonate (PC). These were selected from their nanoporous 
nature and chemical property as well as the potential for integration on a miniaturized silicon 
membrane frame. The whole sensor is enclosed by an external capsule that protects the 
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internal components from the external environment. Sylgard 184 is a polydimethylsiloxane 
(PDMS) that is commonly used in microfluidics and lab-on-a-chip devices, whereas araldite 
2020 (A2020) is a two component epoxy resin that offer an additional degree of mechanical 
support. Both of these (alone or in combination) will be moulded around the sensor assembly 
and cured at room temperature. Type 316L stainless steel (Me) used to encapsulate prototype 
devices was included in these studies for comparison. 
The sensor (Fig. 4) rests in the interstitial fluid (ISF) which represents an ultrafiltrate of blood, 
and which in accordance to previous studies has shown to mirror the glucose concentration in 
blood (97-100).  
 
Fig. 5 Computer-aided design depicting the architecture of the sensor implant (a). The sensor chip, 
incorporating a differential pressure transducer located at the front, followed by the application-
specific integrated circuit, ASIC (including temperature compensation) and components of the 
inductive powering and telemetry interface. The membrane and the inductive coil antenna are 
assembled on the reverse side. The whole unit is encapsulated in epoxy resin (A2020), with a filler 
channel enabling injection of the aqueous osmotic active solution prior to operation. (b) Assembled 
prototype carrier and capsule. An optional venting channel assisted filling in early versions (101) 
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The glucose sensor records the osmotic pressure that is generated in a sensor cavity [1] 
enclosed by a nanoporous membrane [2] and a silicon pressure transducer [3]. The membrane 
and transducers are attached by an adhesive [4] to the sensor carrier [5] and sealed with a 
sealant material [6] forming a flexible buffer against the external capsule [7]. The sensor 
cavity maintains an active solution [8] based on the concanavalin A (Con A) - dextran affinity 
assay used to identify glucose from other components in blood (102;103). The membrane acts 
as an immunological barrier that protects the assay molecules against antibodies that are too 
large to pass through the nanopores. The membrane, sealant and encapsulant will be in direct 
contact with the ISF through the access channel [9], whereas the carrier, adhesive and 
transducer will be in indirect contact through the membrane. The osmotic pressure is 
generated by glucose diffusing through the membrane and displacing dextran from the Con A 
in a competitive manner. The release of dextran increases the free particle concentration 
inside the cavity. This particle increase changes the transmembrane concentration gradient 
which results in an increase in the osmotic pressure inside the cavity due to water diffusing 
through the membrane by the process of osmosis. This process is reversible and the free 
dextran will reattach back to Con A (reducing the net free particle concentration in the cavity) 
as the level of glucose is reduced. 
3.2 Materials description 
A total of 18 different materials were investigated in this project. 14 of these were 
implemented in the first study (Study 1), 15 of these in Study 2 and 3 and eight materials in 
Study 4. All the materials were grouped in accordance to the construction of the device (Table 
2). The commercial nanoporous membranes were chosen to have an average pore diameter 
ranging from below 1 nm (two different polyamide membranes PAR and PATF with 
molecular weight cut-off (MWCO) rated to zero), a cellulose ester membrane (CM) with pore 
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size 2.5 nm, anodic aluminium oxide membrane with pore size 5 nm and a polycarbonate 
membrane with a pore size of 15 nm (polycarbonate with a MWCO of 500 kDa).  
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A membrane with a pores size of 5 nm was the preferred candidate for implementation in the 
osmotic glucose sensor since it permits glucose to pass unhindered through the membrane and 
into the reference chamber (where the osmotic pressure is generated), while retaining the 
larger components of the affinity assay (101;103). Two commercially available membranes 
used in microdialysis catheters were included in Study 4 since these are approved biomaterials 
already in use by medical devices: polyarylethersulphone membrane PAES-1 with MWCO 20 
kDa and polyarylethersulphone membrane mixed with polyamide PAES-2 with MWCO 100 
kDa and a catheter shaft of polyurethane (PU) was used as the negative control for 
microdialysis membranes. 
3.3 Experimental protocol 
The experiments were performed in 24-wells polystyrene microtiter plates. The material 
samples with liquid properties (PDMS, A2020, S3140, S3145, ETek) was prepared by 
administering 0.5 mL of the uncured monomer in the respective wells and subsequently 
polymerized at room temperature (600C for ETek) for 24 hours in accordance to the 
recommendations of the manufacturer. Material samples with a solid structure (Si, SiO2, CT, 
DP) were cut into pieces of 1 cm2. The nanoporous membranes and metal parts were cut into 
circular structures with a surface area of 1 cm2. The microdialysis membranes were delivered 
as catheters with a 30 mm long membrane part that was cut into 1 cm long units and collected 
in groups of 9 pieces that would correspond to the surface area of the other membranes. 
All the material samples (except for the nanoporous membranes) were washed 3 times with 
ethanol and then rinsed with distilled water. The solid materials were additionally treated with 
an ultrasonic bath to remove residual microparticles left behind on the material surface as a 
result of the manufacturing process or dicing of samples. The nanoporous membranes were 
incubated in distilled water overnight in accordance to the manufacturer’s instruction and 
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stored in phosphate buffered saline (PBS). Microdialysis membranes were cut into the pieces 
before each experiment. All the materials used in this study were rinsed with PBS prior to use 
in the experimental protocols. 
The serum model was based on a serum batch from five healthy volunteers (Study 1), whereas 
the whole blood models (with and without soluble anticoagulant) were based on whole blood 
from five healthy volunteers (Study 2, 3 and 4). Serum was prepared by allowing the blood to 
clot at room temperature for two hours. After centrifugation at 2500g for 15 min at 40C, the 
serum was collected and mixed to one batch before being stored at -700C. The whole blood 
was anticoagulated with the thrombin inhibitor lepirudin (Refludan®, Pharmion Germany 
GmbH, Hamburg, Germany) to a final concentration of 50 μg/mL (85;104) for use in Study 2 
and 3. The whole blood without soluble anticoagulant (Study 4) was collected in heparin-
coated tubes and immediately transferred to wells coated with heparin (Carmeda AB, 
Upplands Vasby, Sweden). Informed consent was obtained before blood donation and the 
study was approved by the local ethical committee. 
The experiments were performed by first administering 0.25 mL of serum (Study 1) or 0.5 mL 
of whole blood (Study 2, 3 and 4) in each well containing the respective biomaterial or 
controls. The samples were then incubated at 370C in a climate room with the plate placed on 
a shaker platform in a sealed container. The incubation time depended on the different 
analysis methods and ranged from 20 min for the CD11b expression, 30 min for the 
complement activation study and coagulation assays, 60 min for the surface complement 
activation experiment, β-thromboglobulin (BTG) and MPO release, 120 min for the platelet 
count and finally 240 min for TF expression and cytokines analysis. The coagulation assays 
used native polystyrene wells as controls to validate the effect of the heparin-coated wells for 
incubation of blood without soluble anticoagulant. The plates were placed on a shaker 
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platform and incubated until clear signs of coagulation occurred or up to a maximum of 48 
hours. 
After the incubation was completed, serum (from Study 1) or whole blood (from Study 2, 3 
and 4) was withdrawn from the wells, and immediately transferred on ice. The activation 
process was stopped by adding ethylenediaminetetraacetic acid (EDTA) to a final 
concentration of 20 mM (Study 1,2 and 3), or sodium citrate (Study 4, 1 part in 9 parts of 
whole blood). The serum samples were aliquoted and frozen in -700C, whereas the whole-
blood samples required first to be centrifuged at 1400g for 15 min at 4°C to separate the 
plasma phase that was aliquoted and frozen at -70 °C. Blood used for subsequent platelet 
count (Study 3) was collected in EDTA tubes and delivered to the hospital laboratory for 
analysis. For the BTG assay, 450 μL of blood was aliquoted before adding 50 μL citrate-
theophylline-adenine-dipyridamol (CTAD) buffer (105). The tubes were then immediately 
placed on ice and centrifuged at 2500g for 20 min at 4 °C. After centrifugation, one third of 
the plasma volume in the middle region was collected to prevent platelet contamination. The 
collected plasma was than centrifuged a second time at 2500g for 20 minutes at 4°C. The 
plasma was then collected as previously described and frozen at -70 °C. 
The materials used for the detection of solid-phase complement activation in Study 1 were 
(after the incubation step) rinsed 3 times with PBS containing 0.1% Tween 20 before the TCC 
deposition was immediately analyzed by EIA. 
3.4 Controls 
Heat aggregated immunoglobulin G (HAIGG) and zymosan diluted to a final concentration of 
1 mg/mL served as the positive control for complement activation. The thrombin receptor 
activation peptide (TRAP-6, Bachem AG, Bubendorf, Switzerland) diluted to a final 
concentration of 12.5 μM served as the positive control for the BTG-assay in Study 3 (106). 
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Ultrapure LPS in a concentration of 10 μg/mL was used as the positive control for cytokines, 
whereas wells coated overnight with 0.5 mL 50 μg/mL HAIGG and blocked with 1 mL 1% 
bovine serum albumin (BSA) were used as the positive control for surface complement 
activation. Empty polystyrene wells served as the negative control. 
3.5 Assays 
3.5.1 Enzyme immunoassays 
Enzyme-linked immunosorbent assay (ELISA) 
Enzyme-linked immunosorbent assays (ELISA) based on monoclonal antibodies was used to 
measure the level of both solid-phase and fluid-phase complement activation (both in Study 1) 
since it recognizes the products from the different pathways. The ELISA was also used to 
assess the level of MPO (Study 2), BTG (Study 3 and 4), prothrombin fragment 1+2, PTF 1+2 
and the thrombin-antithrombin complexes, TAT (Study 4). 
Solid-phase complement activation 
The deposition of TCC on the sample surface after incubation in serum was analyzed by 
incubating a monoclonal anti-TCC antibody (clone aE11) for 1 hour to permit reaction with a 
neoepitope exposed in the C9 when incorporated into the C5b-9 complex (107). In parallel 
experiments, the same material samples were incubated with an isotype control IgG2a 
antibody and the plates were then incubated with a biotinylated anti-mouse IgG2a monoclonal 
antibody (both obtained from BD Pharmingen, San Diego, CA) for 45 min. This was followed 
by incubation with streptavidin-conjugated horseradish peroxidase (Amersham Bioscience 
Inc, Piscataway, NJ) for 45 min. Finally, 2,2 azino-di(3-ethyl)-benzthiazoline sulphonate 
containing H2O2 was used as the substrate. The plates were washed 3 times between each 
incubation step in PBS containing 1% Tween 20. Duplicate wells were used in each 
experiment. The data acquired from different plates were compared by standardizing readouts 
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by the use of optical density (OD) in wells coated with HAIGG. All the results were recorded 
when the OD (wavelength of 405/492 nm in the microplate reader Asys Expert 96, Biochrom 
Ltd, Cambridge, UK) in wells coated with HAIGG was around 1. 
Fluid-phase complement activation 
The complement component Bb is an activation marker of the alternative pathway, whereas 
C4d represents the activation of both the classical and the lectin pathways. The intermediate 
product C3bc indicates activation of the common C3 precursor, while TCC represents 
activation of the terminal pathway. 
The components C4d and Bb were quantified using ELISA based on mouse monoclonal 
antibody specific for human C4d and Bb according to the instructions from the manufacturer 
(Quidel, San Diego, CA). The C3bc concentration was measured by an ELISA based on the 
mouse anti-human C3bc antibody (clone bH6) reacting with a neoepitope exposed in C3b and 
C3c after activation of C3. The assay has been described in detail previously (108). The TCC 
concentration was measured by an ELISA based on the mouse anti-human TCC antibody 
(clone aE11) reacting with a neoepitope exposed in C9 when incorporated into C5b-9. This 
assay has also been described in detail previously (109), and was performed according to a 
later modification (110). 
Myeloperoxidase 
The MPO concentration in plasma was measured with a commercial EIA kit (Cat.no HK324, 
Hycult biotech, Uden, The Netherlands) in accordance to manufacturer’s instruction. 
β-thromboglobulin 
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The BTG level in plasma samples was quantified using an EIA based on a rabbit anti-human 
β-thromboglobulin antibodies according to the instructions from the manufacturer (Cat.no 
00950, Diagnostica Stago, Asnieres, France). 
Coagulation and platelet activation assays 
PTF 1+2 and TAT were analyzed in plasma samples by an EIA kit (Enzygnost, both obtained 
from Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany) based on 
monoclonal mouse antibodies to human F1+2 and human thrombin. 
Multiplex assay 
Cytokine and chemokine concentrations in plasma 
The plasma samples were first screened with a 27-plex multiplex cytokine assay (Bio-Plex 
Human Cytokine 27-Plex Panel, Bio-Rad Laboratories Inc., Hercules, CA). Of these, six 
cytokines and chemokines responded significantly and were chosen for further analysis: IL-6, 
TNF-α, IL-1β, IL-8, MCP-1 and MIP-1β. The analysis was performed according to the 
manufacturer’s instructions. 
3.5.2 Flow cytometry 
Flow cytometry was used to measure the level of CD11b expression on PMN surface that was 
presented in Paper 2 and the TF expression on monocyte surfaces as presented in Paper 3. 
CD11b expression 
Blood was withdrawn from the wells containing the biomaterial candidate after a 20 min 
incubation period, and fixated using a 0.5% paraformaldehyde solution for 4 min at 37 °C. 
The blood cells were then protected from light (kept in the dark) and stained at room 
temperature with anti-CD11b-PE antibodies (Cat. no. 333142) or an isotype control IgG2a-PE 
antibodies (cat.no 349053), both obtained from Becton Dickinson (Franklin Lakes, NJ) for 15 
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min. The red blood cells were lysed and the samples centrifuged at 300g for 5 min at 4 °C. 
The supernatants were discarded and the cells were washed twice with 2 mL PBS before 
centrifugation at 300g for 5 min at 4 ºC. The cells were then resuspended in PBS containing 
0.1% albumin and placed on ice in the dark until data acquisition by the flow cytometer 
(FACScan, Becton Dickinson, Franklin Lakes, NJ) was performed. The PMN were gated in a 
FSC/SSC-dotplot, and the mean fluorescence intensity (MFI) values for CD11b were 
calculated. 
Tissue factor expression 
The FITC-conjugated antibody against human TF (Cat.no. 4508CJ, American Diagnostica 
Inc., Stamford, CT) was prepared according to the manufacturer’s instructions and used at a 
final concentration of 50 μg/mL. The IgG1-FITC antibodies (Cat.no. 345815) were used as 
the isotype matched control. Anti-CD14-PE antibodies (Cat.no. 345785, both obtained from 
Becton Dickinson, Franklin Lakes, NJ) was used as a marker of monocytes. After sample 
incubation, the antibody mixture was added and the samples incubated in the dark for 15 min 
at room temperature. The samples were then lysed with 1 mL EasyLyse (S2364, Dako 
Cytomation, Glostrup, Danmark) at room temperature for 15 min, centrifuged at 300g for 5 
min at 4 ºC, washed twice, and analysed immediately with a flow cytometer with the 
threshold put on forward scatter (FACScan, Becton Dickinson, Franklin Lakes, NJ). The 
monocytes were gated in a PE/SSC-dotplot, and the results were recorded as median 
fluorescent intensity (MedFI). 
3.6 Complement inhibition 
As part of the process of evaluating the role that the complement system plays in determining 
the materials biocompatibility, it was required to inhibit part of the cascade process at the C3 
and C5-level. The compstatin analog Ac-I[CV(1MeW)QDWGAHRC]T, which binds to and 
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inhibits cleavage of C3, was produced as previously described together with a control peptide 
(111). The analog was used in Study 2 at final concentrations of: 25 mM; 12.5 mM; 6.25 mM 
and 3.125 mM. Eculizumab (Soliris®, Alexion Pharmaceuticals, Cheshire, CT), a monoclonal 
antibody that specifically binds to the complement protein C5 was used in final concentrations 
of: 50 μg/mL; 25 μg/mL; 12.5 μg/mL and 6.25 μg/mL (Study 2), 50 μg/ml (Study 3), and 100 
μg/ml (Study 4). The whole blood was pre-incubated with these complement inhibitors for 5 
min. before the candidate materials were placed in the wells. 
3.7 Statistical analysis 
The results were statistically compared by one-way analysis of the variance between groups 
(ANOVA) with Bonferroni post test analysis. Data from the experiments with complement 
inhibitors in Study 2 were compared by one-way ANOVA in order to analyze the dose-
dependent decrease of activation. The effect of complement inhibition in Study 3 and 4 was 
evaluated using a two-tailed t-test. Results with a p-value <0.05 was considered as statistically 
significant. All the statistical data were collected and calculated with GraphPad Prism version 
5.01 (GraphPad Software, San Diego CA, USA). 
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4. SUMMARY OF THE MAIN RESULTS 
4.1 Study 1 
This study presents the complement-activating properties of the candidate materials used in 
the initial experiment (Step 1). 
The solid-phase complement activation was measured by the degree of deposition of TCC on 
the material surfaces. Considering corrosion resistant stainless steel (Me), silicon (Si), silicon 
dioxide (SiO2), cellulose ester membrane (CM), and the low temperature co-fired ceramics 
CeramTec GC (CT) and Dupont 951 (DP), the degree of deposition was higher compared to 
the negative control (p<0.05). In contrast, polydimethylsiloxane (PDMS) and silicone 3140 
(S3140) showed a lower degree of deposition than the negative control (p<0.05). The 
deposition of TCC on araldite 2020 epoxy resin (A2020), Epo-Tek 353ND epoxy resin 
(ETek) and silicone 3145 adhesive (S3145) was comparable to the negative control 
(polystyrene). The isotype control antibody revealed a low degree of unspecific binding, 
except for the CM, which displayed high degree of unspecific binding. 
Since the candidates for the membrane group were incompatible, three additional nanoporous 
materials, polyamide (PA), polycarbonate (PC) and anodic aluminium oxide (AAO), which 
exhibited different material composition and pore sizes, were selected for further investigation 
and comparison with the CM. The solid-phase complement activation was comparable for all 
the four membranes, and as evaluated by the deposition of TCC on the membrane surface, 
was found to be significantly higher than the negative control (p<0.05). The antibody used for 
the isotype control confirmed a particularly high unspecific binding to the CM and PA, 
whereas the other two materials, in particular PC, showed markedly less unspecific IgG 
binding. 
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Considering the fluid phase complement activation, the activation products C4d, Bb, C3bc 
and TCC re-confirmed CM to be highly incompatible, whereas PC was the only one of the 
membranes which did not induce any complement activation in the fluid phase.  
4.2 Study 2 
This study demonstrates the PMN activating properties of the candidate materials, as 
evaluated by the surface expression of CD11b and the release of MPO. The effect of 
complement inhibition on PMN activation was also investigated. 
The expression level of CD11b after incubation with three of the membrane candidates (CM, 
PAR, and PATF) was significantly higher compared to the negative control (p<0.05). 
Similarly, the concentration of MPO in plasma after incubation with three of the membrane 
candidates (CM, PAR and PATF) was also significantly higher than the negative control 
(p<0.05). The candidate materials used for the encapsulation (PDMS, A2020, Me), carrier 
(CT and DP), sealing (S3140, S3145 and E-Tek) and the remaining four membrane candidates 
(Si, SiO2, PC, AAO) did not induce CD11b expression and MPO release compared to the 
negative control. 
The three membrane candidates which were shown to activate PMN, were chosen to 
investigate the effect of complement inhibition. Thus, complement inhibition by the C3-
inhibitior compstatin led to a dose-dependent decrease in the level of CD11b expression and 
MPO release induced by all the three materials. Similarly, complement inhibition by the C5-
inhibitor eculizumab decreased the CD11b expression on PMN and MPO release in a dose-
dependent manner. 
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4.3 Study 3 
This study demonstrates the importance of complement in inducing secondary inflammatory 
reactions related to exposure from a series of candidate biomaterials. 
The complement activation products Bb, C3bc and TCC were significantly increased by three 
of the candidate membranes (CM, PAR and PATF) (p<0.01). These membranes were also 
found to significantly increase the concentration of the IL-6, TNF-α, IL-1β and MCP-1 
(p<0.05 for all). The concentration of IL-8 was also significantly increased by these three 
materials as well as for two of the carrier candidates, CT and DP. The concentration of MIP-
1β showed a slightly different pattern by being increased by only Me and CM. 
The expression of TF was significantly higher for the same three membrane candidates CM, 
PAR and PATF. No difference was observed in the expression of TF with any of the other 
materials. The isotype matched control for PAR was, however, significantly higher than the 
negative control so the specificity could not be verified in this case. 
CM, PAR and PATF were included in supplementary experiments to test the hypothesis that 
complement activation is the primary event leading to these secondary reactions. Complement 
inhibition led to a significant decrease in the TF expression on monocytes that were induced 
by PATF and CM, and virtually completely abolishing the expression. PAR showed a high 
level of unspecific binding of the TF antibodies and was therefore excluded from the 
experiment. 
Complement inhibition with eculizumab showed a marked decreased in the pro-inflammatory 
cytokines IL-6, TNF-α and IL-1β after incubation with PATF, and IL-6 and TNF-α level after 
incubation with CM. The incubation with PAR had no effect on the cytokine level. Similarly, 
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complement inhibition significantly decreased the level of the chemokines IL-8 and MCP-1 
after incubation with CM, PAR and PATF, but had no effect on the MIP-1β level. 
4.4 Study 4 
This study presents the coagulation and platelet activation by the membrane materials. The 
use of heparin coated wells permitted the use of a modified whole blood model without a 
soluble anticoagulant. 
A whole blood model without a soluble anticoagulant was validated in an additional 
experiment that compared the effects of heparin-coated plates with native uncoated 
polystyrene. A complete coagulation of blood in the polystyrene wells was registered within 
14 minutes (range 10 – 16 minutes, n=7). In contrast, whole blood from the same needle 
drained in heparin-coated wells (n=7) did not clot during 48 hours of incubation, when the 
experiment was terminated. Thus, the heparin-coated model was used in subsequent 
experiments. 
The results showed that the PTF 1+2 was significantly increased after incubation with PAR in 
whole blood (p<0.01) and insignificantly increased after incubation with PATF. No increase 
in PTF 1+2 was seen after incubation with any of the other membrane materials chosen in the 
study. The concentration obtained with S3140, which was included in the experiments as a 
biocompatible material, was lower than the negative control. The level of TAT was 
significantly increased only after incubation with PAR in whole blood (p<0.01). An non-
significant increase was observed by PATF. The level of BTG was significantly increased 
after incubation with five of the materials in whole blood, most pronounced for PAR, 
followed by PATF, PC, PAES-1 (p<0.01 for all) and PAES-2 (p<0.05)).  
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Complement inhibition with eculizumab had no effect on the concentration of PTF 1+2, TAT 
or BTG in the plasma samples. A TCC assay was performed to confirm that eculizumab 
inhibited the complement system. Consequently, the addition of eculizumab to whole blood 
completely abolished TCC production in the samples 
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5. DISCUSSION 
The most important ethical goal for the use of artificial materials in medicine is to avoid any 
harmful effects on the human body. “Primarum non nocere”, the phrase known from 
Hippocrates oath concerning biomaterials meant that all interventions, including the 
implantation of artificial materials, should be safe for the patient and not elicit any dangerous 
reactions. 
The safety of implantable devices does primarily depend on the biocompatible nature of the 
implant materials and the biological processes that is triggered at the site of implantation. The 
activation of biological cascades like the complement system, the coagulation system and the 
production of pro-inflammatory cytokines can both alter the sensor function and be harmful 
for the patient. This is especially important to consider regarding the potential use of 
implantable glucose sensors that would be capable of continuously monitoring the level of 
glucose in patients suffering from diabetes. Any infection or inflammatory reaction caused by 
the sensor implantation would have serious effects on the therapeutic treatment as well as the 
quality of life if the sensor was to malfunction or give faulty signals. In this project, we have 
evaluated a selection of candidate materials that were intended for use in an osmotic glucose 
sensor. The aim was to identify potential activating properties that could deem them 
acceptable or unacceptable for use in an implanted device. It was particular important to 
evaluate all the materials that would be incorporated, even if some of them would not be in 
direct contact with the interstitial fluid where the sensor would reside. Any mechanical 
damage to the sensor capsule would expose the underlying materials to the ISF and thus the 
potential incompatibility of these sensor components could lead to an inflammatory response. 
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Performing an in vitro analysis of the biocompatibility of a material is the first and absolutely 
necessary step to consider. In accordance to the International standard ISO 10993 part 4 (3) 
the appropriate methods were used to study the biocompatibility in vitro. The combined 
evaluation of the complement activation, the PMN activation, the cytokine secretion and the 
coagulation and platelet activation presented and almost complete picture of the in vitro 
immune response to implantable biomaterial candidates. 
5.1 Complement activation on both solid and fluid phase 
The complement system is considered to be the first line of defence of the immune system 
that is activated in response to the implantation of biomaterials. Literature have linked 
complement with the immune response to foreign materials and thereby their biocompatible 
nature (8;18;62;112;113). Therefore, the starting point of our initial study presented in Paper 1 
was to use a serum model to investigate the activation potential of complement without 
having to consider any signals from other components of the immune system. 
Complement activation by biomaterials is initiated by proteins that are adsorbed onto the 
material surface (48;61). This activation then leads to a spreading of this processes to the 
surrounding tissue, e.g. by the fluid phase. The degree of complement activation can clearly 
discriminate between biomaterials. Previous studies have suggested that both solid and liquid 
phases of complement activation are required to examine biomaterials (114). The initiation of 
the complement cascade at the surface of biomaterials with subsequent C3b absorption 
initiates formation of the enzyme C3-convertase that triggers activation of the alternative 
pathway (112). Moderately biocompatible biomaterials limit complement activation to the 
solid phase only, which makes it difficult to detect the activation products with the commonly 
known ELISA method. Biomaterials with a porous structure may additionally adsorb 
activation products that mask complement-activating properties of the material. 
52 
 
By evaluating both phases in study 1, the advantage of a combined approach was apparent by 
revealing different activating properties of the investigated materials. From the initial 
screening, two material candidates (the capsule candidate PDMS and the silicone adhesive 
S3140) activated complement to a lower degree than the negative control and was therefore 
regarded as biocompatible (Table 3). PDMS have been used in both implantable devices and 
biosensors (115) and its good biocompatibility have been confirmed both in vitro (116;117) 
and in vivo (118). Silicone-based polymers are also widely used as cosmetic implants as well 
as in contact lenses, and several studies have hence confirmed also these as biocompatible 
materials (119-121). The capsule candidate A2020, and the two sealing candidates ETek and 
S3145 were regarded as fairly biocompatible as the level of complement activation was 
comparable to the negative control. However, materials that activated complement in the solid 
phase only, was in this study considered as moderately biocompatible and hence deemed 
suitable candidates for implantation if further surface modifications are able to neutralise the 
observed immunological effects. Not a single candidate from the membrane group expressed 
the required biocompatible properties comparable to the negative control or better, which 
made this group a challenging issue, especially since the membrane forms the most central 
part of the sensors functional interface. The CM membrane as well as the additional 
membrane candidates (PA, AAO) expressed complement-activating properties in both the 
solid and the liquid phase. However, PC activated complement in the solid phase only and 
based on the results of the study could be regarded as the only membrane suitable for use in 
an implantable device (considering the limitations given above). The complement-activating 
properties of membrane candidates in literature have been related to the surface structure, the 
chemical composition (10) and the different pore sizes of the membrane materials (15). The 
membrane candidates that were examined in this project offer various pore sizes, as indicated 
by their molecular weight cut-off (MWCO, from zero for PA membrane to 5000 Da for CM). 
53 
 
The comparable magnitude of complement activation triggered by membranes with different 
pore size confirms the chemical structure and the degree of protein absorption on the surface 
as the major contributor of their complement-activating properties. 
5.2 Activation of the immune cells and the inflammation cascade 
The use of a whole blood model permitted further evaluation of these candidate materials as 
presented in Paper 2 and Paper 3 (85). This model allowed us to examine the interaction 
between the different inflammation cascades and the evaluation of blood cell activation. PMN 
is one of the first immune cells to appear at the site of implantation (39) and the primary role 
of these cells is to combat any infectious organism (43;44) with the release of various amount 
of cytokines, chemokines and enzymes. In the case of biomaterial implantation, the activation 
of this cell has a negative effect (40-42). The overactivation of PMN results in the release of 
an excessive amount of biologically active substances that does not only accelerate the 
healing process and combat infection, but could also lead to the damage of the implant and its 
materials. Our experiments identified a significant increase in PMN activation, TF expression 
on monocyte surface and cytokine concentrations after incubation with three of the membrane 
candidates (CM, PAR and PATF). The results are an agreement with study 1 and confirmed 
that these three materials are inappropriate candidates for use in an implantable device in their 
unmodified forms. 
Based on the results from study 1 we could hypothesize that the inflammatory reaction was 
mediated with complement. Literature have suggested that complement inhibition prevents 
the production of inflammatory cytokines and platelet activation (93;94), and our experiments 
with the C3-inhibitor compstatin and the C5-inhibitor eculizumab confirmed this hypothesis. 
The experiment with eculizumab (that blocks the complement at the C5-level), confirmed the 
primary role of the C5-dependent mechanism of the inflammatory response. The dose-
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dependent decrease of PMN activation and inflammatory response (CM, PAR and PATF) 
with complement inhibitors, confirmed complement as the primary inducer of the secondary 
inflammation response. 
Since the complement system determines the inflammatory response to implanted 
biomaterials, a novel approach to the evaluation of materials biocompatibility can be 
proposed. The complement activation by biomaterials can be used as a primary screen of the 
biocompatibility and can be used as a prognostic marker of inflammatory reactions to 
implantable devices. The use of TCC to screen the complement activation gives more 
advantages compared to another markers because of the stability of the TCC molecule in vitro 
compared to the highly labile C3 molecule (122). 
Some of the materials that were claimed as incompatible in our study are known biomaterials 
that have been used in medical devices before. The CM membrane especially is a known 
complement activator. Clinical studies of dialysis membranes suggested (5;123-126) that 
cellulose is not biocompatible, and which was confirmed in our experiments. Polyamide that 
in clinical studies have showed good biocompatibility (127-129), triggered a substantial 
activation of complement in our study. This discrepancy can be explained by the different 
tests and models that were used as well as the different types of polyamides. Most of the 
literature studies on the biocompatible nature of polyamide membranes were performed in 
clinical conditions where patient-to-patient variations could significantly influence the results. 
The use of the in vitro whole-blood model in our studies decrease the variability of the results 
and allowed the interaction between the immune cells, the inflammatory network and the 
complement cascade to be examined. 
Another component of the sensor, Con A, was not included in the study despite its known 
toxic activity. The liquid properties of Con A and the small volume used in the 
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microfabricated sensor cavity will prompt this component to dissolve into the surrounding 
tissue without harmful consequences (130).  
5.3 Activation of coagulation and platelets 
The activation of the coagulation cascade and platelets was further explored in study 4. Since 
thrombin is irreversibly blocked in a whole blood model that have been anticoagulated with 
lepirudin, the use of such a model for the evaluation of coagulation and platelets activation 
would be substantially limited. Our study used a modified whole blood model without soluble 
anticoagulant, and required incubation of the material samples in wells coated with heparin. 
This model permitted us to create conditions that were close to in vivo and to examine the 
interaction of the coagulation system and platelets with the complement system, blood cells 
and the inflammatory cascade. The clear difference in coagulation time between wells coated 
with heparin and polystyrene wells confirmed protective effect of heparin coating. 
Both PAR and PATF activated the coagulation cascade as it was shown by the measured 
increase in the PTF 1+2 and TAT concentration in the plasma (although the difference with 
the negative control value was not statistically significant for PATF). In contrast, the cellulose 
membrane that was shown to be incompatible in our previous studies as well as in several 
clinical studies (5;123;124;126), did not induce coagulation or platelet activation. This finding 
is in accordance to clinical studies of haemodialysis membranes where a blood contact with 
polyamide membrane led to significantly higher levels of TAT compared to a modified 
cellulose membrane (131). 
The platelet activation measured by BTG concentration in plasma was increased for five of 
the materials. In contrast, in Study 3 using a whole blood model with lepirudin as 
anticoagulant none of the candidate materials used activated platelets. Lepirudin irreversibly 
blocks thrombin and abrogate the influence of this molecule on platelets in this model. Since 
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thrombin is a well-known platelet activator (75;76), we modified the whole blood model by 
coating the wells with heparin and omitting the addition of lepirudin, thus leaving thrombin 
functionally active in the fluid-phase. In contrast to our data using lepirudin (Study 3), the five 
materials including the membranes used in the previous study, triggered platelet activation as 
show by the increased BTG concentration. These findings suggest that membrane-induced 
thrombin formation activate platelet and underscores the importance of selecting a suitable 
model in the studies of coagulation and platelets activation by biomaterials. 
The polyamide membranes PAR and PATF that triggered coagulation and platelet activation 
in Study 4, was also shown to be incompatible materials from the results presented in Study 1, 
2 and 3 (activation of coagulation, blood cells and secretion of cytokines). These processes 
were confirmed to be complement-mediated (PATF), and based on these results we could 
hypothesize that coagulation and platelet activation are also mediated by complement 
activation. However, additional experiments with the complement C5 inhibitor eculizumab 
showed that the complement system, at the level of C5, had no effect on the coagulation and 
platelet activation with the candidate membranes. Accordingly, we assume that complement-
independent mechanisms are responsible for the pro-coagulant properties of the materials. 
Both in clinical studies (29) and in vitro (132) it has previously been shown that any contact 
of biomaterials with blood leads to the activation of the contact system with further thrombin 
generation or thrombosis formation as the result. The inhibition of complement at the level of 
C5 did not inhibit the contact system. Complement inhibition had no effect on platelet 
activation as well, and the increased concentration of BTG can be explained from a direct 
interaction of platelets with the surface of the materials with further amplification in the 
presence of thrombin (32). 
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5.4 Evaluating the performance of implantable devices 
The in vitro evaluation of biocompatibility is a primary tool (133) used to select potential 
biomaterials for use in implantable devices. However, data from the literature shows that the 
results of in vitro assays does not always confirm to the results that have been observed using 
the same materials in vivo and is therefore not a guarantee of device biocompatibility 
(82;134). Still, several of the candidate materials used in our studies have been confirmed as 
biocompatible also in vivo. PDMS that in our studies was found to be biocompatible in vitro 
has also been confirmed as biocompatible in vivo (118;135) due to the absence of 
inflammatory markers at the site of implantation. The biocompatibility of silicone implants 
and silicon materials have also been confirmed in vivo with acceptable levels of tissue 
inflammatory response both for the silicone elastomer and the silicon nitride used in the study 
(120;136). The correlation between the in vitro and the in vivo cytokines profile for 
biomedical polymers was confirmed by Anderson (137), suggesting that the results from the 
in vivo studies that were similar in nature to our in vitro findings confirmed the use of a whole 
blood model as the closest in vitro experimental representative of the in vivo environment. 
The primary role of complement in initiating the PMN activating properties, TF expression 
and cytokine production in response to biomaterials exposure, renders complement as a 
preferred tool to use in order to identify suitable materials for subsequent in vivo studies. 
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6. FUTURE PERSPECTIVES 
The material candidates investigated in Study 1-4 were classified as either biocompatible, 
fairly biocompatible, moderately biocompatible or incompatible (Table 3). Materials with 
biocompatible (level of complement, inflammation, PMN and coagulation activation lower 
than the negative control) and fairly biocompatible (level of activation comparable with the 
negative control) properties were proposed to be good candidates for use in implantable 
devices and for future in vivo studies. The materials that were classified as moderately 
biocompatible, activated complement in the solid phase or induced limited activation of the 
PMN, the inflammation cascade or the coagulation. These could only be considered as 
desirable candidates if they were subject to further improvement by for instance surface 
modifications. However, the materials that were found to be inbiocompatible (high degree of 
activation in several assays), were considered as unsuitable candidates for use in any 
implantable device. 
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The main goal of surface modification is to shield the underlying artificial surface away from 
the immune system (138). Several strategies exist that improves the materials 
biocompatibility. These include surface modification with hydrogels, surfactants and heparin, 
as well as the modification of surface topography; and the application of flow-based systems 
that decreased biofouling and protein adsorbtion to a material surface (69). Since complement 
has been confirmed as the primary inducer of the inflammatory response to biomaterials, 
surface modifications with complement inhibitors or native regulators may represent a 
promising method to use. Polyethylene glycol (PEG) coating is found to decrease the 
nonspecific protein adsorption (69;139;140) and therefore assists in decreasing the activation 
of the coagulation system and the subsequent adhesion of platelets and cells (141). However, 
PEG-coated surfaces does not prevent the activation of complement (17;139). Instead, coating 
the surface with heparin may have a more potent effect on the immune system components. It 
has been shown to that heparin coating decreases level of coagulation activation and 
inflammatory reaction as well as that of complement activation (8;93;95). The adsorption of 
thrombomodulin on a material surface has been used to improve the blood compatibility and 
have showed promising effect on the coagulation and complement systems. However it 
demonstrated no effect on platelet activation (142). The immobilisation of apyrase effectively 
prevents platelet activation and adhesion, but this method had no effect on suppressing the 
complement activation (143). Factor H, a primary regulator of the alternative pathway 
activation (24) have showed promising results to prevent complement activation on material 
surface in literature studies (17;144) and presents a suitable method to improve the 
complement activating properties of moderately biocompatible materials. 
Modification of material surface with adhesion ligands and growth factors that prevent 
fibrosis and controls neovascularisation is also possible, but the sensor interface is challenging 
to modify since the sensor should maintain appropriate analyte transport through the multi-
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layer coating. For this reason, highly water-swollen hydrogels with minimal impact to sensor 
interface can be use for surface modification of implantable sensors. 
All of these methods, alone or in combination, have the potential to reduce the immune 
response of implantable medical devices and their materials. As well as posing a direct effect 
on the immune system components, the immobilised layer would also need to maintain a high 
level of stability with time in order to have any noticeable impact on the lifespan of the device 
(145). Achieving long term operation of a medical implant will facilitate the continuous 
surveillance of key physiological parameters as part of an improved therapeutic regime. This 
will facilitate an early intervention that will help to decrease the consequences from acute 
physiological events (heart attach, stroke) as well as preventing long term complications from 
chronic diseases such as diabetes. 
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7. CONCLUSIONS 
1. Discriminating between complement activation in the solid and the fluid phase 
illustrated the importance of investigating both phases to determine the level of 
biocompatibility of the material candidates in the serum model. 
2. Materials that activated complement in both the solid and the fliud phase (CM, PAR 
and PATF) were regarded as incompatible and were considered as unsuitable 
candidates for implementation in an implantable device. 
3. The incubation of three of the 15 materials (CM, PAR and PATF) in whole-blood with 
a soluble anticoagulant induced a significant inflammatory response with an increased 
level of CD11b expression on PNM, MPO release, TF expression on monocytes and 
an increased level of cytokines and chemokines. By activating this parameters they 
would not be considered as suitable candidates for use in implantable devices. 
4. Complement inhibition completely abolished or significantly reduced the 
inflammatory response by CM, PAR and PATF in a dose-dependent manner that 
confirmed the complement system as a primary inducer of the inflammatory response 
to material candidates. 
5. The use of a modified whole blood model without a soluble anticoagulant is 
considered to be a suitable in vitro assay for the investigation of the coagulation and 
platelet activation triggered by biomaterials. 
6. The complement system is a primary event that is responsible of inducing an immune 
response to biomaterials. Nevertheless, the inclusion of haemostatic assays in whole 
blood without a soluble anticoagulant is required for to evaluate the biocompatibility, 
since it permits the study of complement-independent mechanisms 
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The biocompatibility of candidate materials in this project was studied using a wide spectrum 
of assays for complement, coagulation and PMN activation as well as cytokine production. 
The existing whole blood model was modified in order to study the coagulation cascade 
without using a soluble anticoagulant. The results presented in this Thesis suggest that 
complement activation is an important factor to consider as the initial screening marker of 
biocompatibility. This activation was to a great extent responsible for the inflammatory 
reaction induced by the biomaterial candidates in the other models that were investigated. 
Since the in vitro environment can be different from the conditions in vivo, there is a 
possibility that the materials that do not activate complement and inflammatory cascades in 
vitro, might turn out to be incompatible in vivo. Future studies will seek to correlate the 
results from the in vitro assays with in vivo studies. 
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